Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ANI Pharmaceuticals Inc (ANIP)
NASDAQ:ANIP
Holding ANIP?
Track your performance easily
ANIP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$48.20 - $70.81
Previous Close$61.05
Volume40.04K
Average Volume (3M)332.98K
Market Cap
$1.28B
Enterprise Value$1.33B
Total Cash (Recent Filing)$240.11M
Total Debt (Recent Filing)$285.24M
Price to Earnings (P/E)49.9
Beta0.82
Next Earnings
Nov 06, 2024EPS Estimate
$1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.22
Shares Outstanding21,030,069
10 Day Avg. Volume510,387
30 Day Avg. Volume332,980
Standard Deviation0.12
R-Squared0.10
Alpha-0.00241
Financial Highlights & Ratios
Price to Book (P/B)2.82
Price to Sales (P/S)2.34
Price to Cash Flow (P/CF)18.10
P/FCF Ratio17.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.26
Enterprise Value/Gross Profit7.49
Enterprise Value/Ebitda14.03
Forecast
1Y Price Target
$79.00Price Target Upside29.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
ANI Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
AcquisitionANI completed the Alimera Sciences deal, bolstering its rare disease business with a global commercial ophthalmology franchise.
Financial PerformanceANI comfortably beat revenue estimates for the ninth straight quarter—led by Cortrophin Gel upside and continued generics execution.
Revenue GuidanceThe Street was happy to see 2024 revenue guidance raised by more than the beat—again driven by Cortrophin Gel, and with unchanged EBITDA margin.
Bears Say
Acquisition DelaysClosure delays of the Alimera acquisition imply potential issues with manufacturing deficiencies of Yutiq.
Legal And Contractual DisputesAlimera announced it has taken legal action against ANI for failure to fulfill its contractual obligation to close the transaction.
Regulatory IssuesAn FDA Warning Letter was issued to Alimera’s third-party manufacturer of Iluvien and Yutiq.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
ANIP FAQ
What was ANI Pharmaceuticals Inc’s price range in the past 12 months?
ANI Pharmaceuticals Inc lowest stock price was $48.20 and its highest was $70.81 in the past 12 months.
What is ANI Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is ANI Pharmaceuticals Inc’s upcoming earnings report date?
ANI Pharmaceuticals Inc’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were ANI Pharmaceuticals Inc’s earnings last quarter?
ANI Pharmaceuticals Inc released its earnings results on Aug 06, 2024. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.07.
Is ANI Pharmaceuticals Inc overvalued?
According to Wall Street analysts ANI Pharmaceuticals Inc’s price is currently Undervalued.
Does ANI Pharmaceuticals Inc pay dividends?
ANI Pharmaceuticals Inc does not currently pay dividends.
What is ANI Pharmaceuticals Inc’s EPS estimate?
ANI Pharmaceuticals Inc’s EPS estimate is $1.07.
How many shares outstanding does ANI Pharmaceuticals Inc have?
ANI Pharmaceuticals Inc has 21,030,070 shares outstanding.
What happened to ANI Pharmaceuticals Inc’s price movement after its last earnings report?
ANI Pharmaceuticals Inc reported an EPS of $1.02 in its last earnings report, beating expectations of $0.95. Following the earnings report the stock price went up 6.981%.
Which hedge fund is a major shareholder of ANI Pharmaceuticals Inc?
Among the largest hedge funds holding ANI Pharmaceuticals Inc’s share is Hussman Strategic Advisors Inc. It holds ANI Pharmaceuticals Inc’s shares valued at 3M.
---
ANI Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$79.00 (29.51% Upside)
$79.00 (29.51% Upside)
Blogger Sentiment
Bullish
ANIP Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 21.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.61%
12-Months-Change
Fundamentals
Return on Equity
5.66%
Trailing 12-Months
Asset Growth
7.15%
Trailing 12-Months
Company Description
ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.
---
ANIP Earnings Call
Q2 2024
0:00 / 0:00
---
ANIP Stock 12 Month Forecast
Average Price Target
$79.00
▲(29.51% Upside)
Technical Analysis
Amphastar Pharmaceuticals
―
Dr Reddy's Laboratories
―
Harrow Health
―
Bausch Health Companies
―
Best Analysts Covering ANIP
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+22.15%
reiterated a buy rating 3 days ago
Copying Oren Livnat's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +22.15% per trade.
---